Justine R Seivright1, Erin Collier1, Tristan Grogan2, Marcia Hogeling3, Vivian Y Shi4, Jennifer L Hsiao3. 1. David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 2. Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 3. Division of Dermatology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA. 4. Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Abstract
BACKGROUND/ OBJECTIVES: Hidradenitis suppurativa (HS) is understudied in the pediatric population. Adult HS patients are known to have a high comorbidity burden. We aimed to describe physical and psychosocial comorbidities in a cohort of pediatric HS patients. METHODS: A retrospective chart review of pediatric HS patients at a single academic institution was conducted. Data on patient demographics, disease characteristics, and physical and psychosocial comorbidities in pediatric patients with HS were collected and analyzed. RESULTS: Seventy-three pediatric patients were included in this study, 81% female. Mean (SD) age of HS disease onset was 12.6 (2.9) years. Comorbid conditions were reported in 68 of 73 (93%) patients. Significantly increased rates of several comorbidities were seen in our cohort as compared to the general US pediatric population. Metabolic and endocrine abnormalities were prevalent, with 52% (22/42) patients with obesity and 10% (6/59) with polycystic ovary syndrome. The most common cutaneous comorbidity was acne vulgaris, seen in 37% (27/73) of patients. Over one quarter (21/73, 29%) of patients had either an anxiety or depression disorder. Almost one-fifth (14/73, 19%) of our cohort had a diagnosis of asthma and other reactive airway diseases. Only one-third (24/73, 33%) of patients had documentation regarding impact of HS on their daily life. Overall, comorbidities largely did not significantly differ based on race, gender, or disease severity. CONCLUSIONS: Pediatric patients with HS face a high-comorbidity burden, especially with psychiatric conditions. Early identification, including routine mental health screening, and management of comorbidities is warranted in the pediatric HS population.
BACKGROUND/ OBJECTIVES: Hidradenitis suppurativa (HS) is understudied in the pediatric population. Adult HS patients are known to have a high comorbidity burden. We aimed to describe physical and psychosocial comorbidities in a cohort of pediatric HS patients. METHODS: A retrospective chart review of pediatric HS patients at a single academic institution was conducted. Data on patient demographics, disease characteristics, and physical and psychosocial comorbidities in pediatric patients with HS were collected and analyzed. RESULTS: Seventy-three pediatric patients were included in this study, 81% female. Mean (SD) age of HS disease onset was 12.6 (2.9) years. Comorbid conditions were reported in 68 of 73 (93%) patients. Significantly increased rates of several comorbidities were seen in our cohort as compared to the general US pediatric population. Metabolic and endocrine abnormalities were prevalent, with 52% (22/42) patients with obesity and 10% (6/59) with polycystic ovary syndrome. The most common cutaneous comorbidity was acne vulgaris, seen in 37% (27/73) of patients. Over one quarter (21/73, 29%) of patients had either an anxiety or depression disorder. Almost one-fifth (14/73, 19%) of our cohort had a diagnosis of asthma and other reactive airway diseases. Only one-third (24/73, 33%) of patients had documentation regarding impact of HS on their daily life. Overall, comorbidities largely did not significantly differ based on race, gender, or disease severity. CONCLUSIONS: Pediatric patients with HS face a high-comorbidity burden, especially with psychiatric conditions. Early identification, including routine mental health screening, and management of comorbidities is warranted in the pediatric HS population.
Authors: Peter Theut Riis; Ditte Marie Saunte; Viktoria Sigsgaard; Axel Patrice Villani; Philippe Guillem; José C Pascual; Naomi N Kappe; Annika M J D Vanlaerhoven; Hessel H van der Zee; Errol P Prens; Moetaz El-Domyati; Hossam Abdel-Wahab; Nayera Moftah; Rania Abdelghani; Eugenia Agut-Busquet; Jorge Romaní; Carol Hlela; Lerinza van den Worm; Vincenzo Bettoli; Giada Calamo; Mehmet Ali Gürer; Burcu Beksaç; Lukasz Matusiak; Amelia Glowaczewska; Jacek C Szepietowski; Lennart Emtestam; Jan Lapins; Hassan Riad Kottb; Mohammad Fatani; Lisa Weibel; Martin Theiler; Maïa Delage-Toriel; Thi Thanh Hong Lam; Aude Nassif; Pierre-Andre Becherel; Mateja Dolenc-Voljc; Nejib Doss; Dorra Bouazzi; Farida Benhadou; Veronique Del Marmol; Gregor B E Jemec Journal: Arch Dermatol Res Date: 2020-03-12 Impact factor: 3.017
Authors: Carmen Liy-Wong; Mary Kim; A Yasmine Kirkorian; Lawrence F Eichenfield; Lucia Z Diaz; Amir Horev; Megha Tollefson; Teresa Oranges; Roderic Philips; Yvonne E Chiu; Ghazal Ghafari; Justin D Arnold; Jessica Sprague; Henry Nguyen; Stephanie Wan; Eshetu G Atenafu; Elena Pope; Jill Hamilton; Haley B Naik; Irene Lara-Corrales Journal: JAMA Dermatol Date: 2021-04-01 Impact factor: 10.282
Authors: Amit Garg; Neeta Malviya; Andrew Strunk; Shari Wright; Afsaneh Alavi; Raed Alhusayen; Ali Alikhan; Steven D Daveluy; Isabelle Delorme; Noah Goldfarb; Wayne Gulliver; Iltefat Hamzavi; Tarannum Jaleel; Alexa B Kimball; Joslyn S Kirby; Mark G Kirchhof; Janice Lester; Hadar Lev-Tov; Michelle A Lowes; Robert Micheletti; Lauren A Orenstein; Vincent Piguet; Christopher Sayed; Jerry Tan; Haley B Naik Journal: J Am Acad Dermatol Date: 2021-01-23 Impact factor: 15.487